Analysis of Immunostaining during Mohs Micrographic Surgery to Improve Detection of Negative Surgical Margins in Patients with Squamous Cell Carcinoma and Chronic Lymphocytic Leukemia (CLL)/ Non-Hodgkins Lymphoma (NHL)


About this study

The goal of this study is to evaluate the use of immunostains during Mohs micrographic surgery (MMS) will improve detection of negative surgical margins in patients with cutaneous squamous cell carcinoma (cSCC) and chronic lymphocytic leukemia (CLL)/non-Hodgkin lymphoma (NHL). The study will also aim to evaluate the use of immunostains during MMS to improve the outcomes (local recurrence, metastasis, and disease-specific death) in patients with cSCC and CLL/NHL.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults (> 18 years of age)
  • Existing diagnosis of CLL/NHL
  • New diagnosis of cutaneous squamous cell carcinoma

Exclusion Criteria: 

  • Existing diagnosis of recurrent or metastatic cutaneous squamous cell carcinoma
  • Existing diagnosis of underlying genodermatosis with associated increased risk of cutaneous squamous cell carcinoma (e.g.xeroderma pigmentosum


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Christian Baum, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer